Kemadrin (Procyclidine Hydrochloride)

Procyclidine works by competitively blocking muscarinic acetylcholine receptors in the central nervous system, especially within the basal ganglia. This antagonism lowers cholinergic activity, helping to restore the dopamine‑acetylcholine balance that is disrupted in Parkinsonian states and drug‑induced movement disorders.

The appropriate dose of Kemadrin is determined by a qualified prescriber based on the individual patient's condition, response, and tolerability. Dosing regimens are tailored to each patient and should follow the prescribing information provided by the healthcare professional.

Kemadrin is classified as a prescription‑only medication and should only be used during pregnancy or lactation if the potential benefit justifies the potential risk to the fetus or infant. Clinicians must evaluate the risk‑benefit profile for each patient and consider alternative therapies when appropriate.

To order Kemadrin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Kemadrin (Procyclidine) belongs to the anticholinergic class, which differs from dopaminergic agents such as levodopa or dopamine agonists. While anticholinergics are particularly effective for tremor and drug‑induced extrapyramidal symptoms, they may have a higher incidence of anticholinergic side effects, making patient selection and monitoring essential.

Kemadrin tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture and direct sunlight, and ensure that it is out of reach of children and pets.

Kemadrin is administered orally, typically as a tablet taken with or without food as directed by the prescribing physician. The exact timing and frequency depend on the individual treatment plan and should be followed according to the healthcare provider's instructions.

Serious risks of Kemadrin include acute glaucoma, severe tachycardia, and rare neuroleptic malignant‑like syndrome, which can present with high fever, muscle rigidity, and autonomic instability. Patients should seek immediate medical attention if they experience sudden visual changes, rapid heart rate, or unexplained fever and rigidity.

Kemadrin is contraindicated in patients with known hypersensitivity to Procyclidine or other anticholinergics, those with narrow‑angle glaucoma, severe urinary retention, or uncontrolled tachyarrhythmias. Caution is also advised for elderly patients and individuals taking multiple anticholinergic medications.